川芎清脑颗粒联合硫酸软骨素治疗偏头痛的临床研究

目的探讨川芎清脑颗粒联合硫酸软骨素治疗偏头痛的临床疗效。方法选取2017年3月—2018年3月在陕西省核工业二一五医院治疗的偏头痛患者76例,根据用药的差别分为对照组(38例)和治疗组(38例)。对照组口服硫酸软骨素钠片,0.6 g/次,3次/d;治疗组在对照组基础上口服川芎清脑颗粒,10 g/次,3次/d。两组患者均治疗4周。观察两组患者临床疗效,同时比较治疗前后两组患者临床症状评分、血清学指标和脑血流情况。结果治疗后,对照组临床有效率为81.58%,显著低于治疗组的97.37%,两组比较差异具有统计学意义(P0.05)。治疗后,两组头痛发作次数、头痛发作持续时间和头痛发作程度评分均明显降低(P0.05),且治疗组患者临床症状评分明显低于对照组(P0.05)。治疗后,两组患者血清高敏C反应蛋白(hs-CRP)、基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)和溶血磷脂酸(LPA)水平均显著降低(P0.05),且治疗后治疗组这些血清学指标明显低于对照组(P0.05)。治疗后,两组患者大脑前动脉(ACA)、大脑中动脉(MCA)、大脑后动脉(PCA)、基底动脉(BA)、椎动脉(VA)的平均血流速度(Vm)均显著降低(P0.05),且治疗后治疗组脑血流情况明显优于对照组(P0.05)。结论川芎清脑颗粒联合硫酸软骨素治疗偏头痛可有效改善患者临床症状,降低血清hs-CRP、MMP-9、VEGF、LPA水平,有利于脑血流速度改善。

Clinical study on Chuanxiong Qiangnao Granules combined with chondroitin sulfate in treatment of migraine

Objective To investigate the clinical efficacy of Chuanxiong Qiangnao Granules combined with chondroitin sulfate in treatment of migraine. Methods Patients (76 cases) with migraine in No.215 Hospital of Shaanxi Nuclear Industry from March 2017 to March 2018 were divided into control (38 cases) and treatment (38 cases) groups based on different treatments. Patients in the control group were po administered with Chondroitin Sulfate Sodium Tablets, 0.6 g/time, three times daily. Patients in the treatment group were po administered with Chuanxiong Qiangnao Granules on the basis of the control group, 10 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptoms scores, the serological indexes, the change of cerebral blood flow in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 81.58%, which was significantly lower than 97.37% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the headache attack frequency, duration of headache attack and headache severity scores in two groups were significantly decreased (P<0.05), and the clinical symptoms scores in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the serum hs-CRP, MMP-9, VEGF, and LPA levels in two groups were significantly decreased (P<0.05), and the serological indexes in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the average flow velocity of ACA, MCA, PCA, BA, and VA in two groups was significantly decreased (P<0.05), and the change of cerebral blood flow in the treatment group after treatment was significantly better than that in the control group (P<0.05). Conclusion Chuanxiong Qiangnao Granules combined with chondroitin sulfate in treatment of migraine can effectively improve the clinical symptoms and reduce the serum level of hs-CRP, MMP-9, VEGF and LPA, which is beneficial to the improvement of cerebral blood flow velocity.